Powder: -20°C for 3 years | In solvent: -80°C for 1 year
O-1602 is a novel GPR55 agonist, an atypical cannabinoid associated with the central nervous system and obesity, and is a candidate compound for the treatment of cystitis.O-1602 promotes hepatic steatosis through GPR55 and PI3 kinase / Akt / SREBP-1c signalling in mice.O-1602 induces, in a GPR3-independent manner, in Hep55B cells with elevated intracellular calcium.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 9,500 | |||
5 mg | 在庫あり | ¥ 22,500 | |||
10 mg | 在庫あり | ¥ 35,500 | |||
25 mg | 在庫あり | ¥ 72,000 | |||
50 mg | 在庫あり | ¥ 113,500 | |||
100 mg | 在庫あり | ¥ 165,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 24,500 |
説明 | O-1602 is a novel GPR55 agonist, an atypical cannabinoid associated with the central nervous system and obesity, and is a candidate compound for the treatment of cystitis.O-1602 promotes hepatic steatosis through GPR55 and PI3 kinase / Akt / SREBP-1c signalling in mice.O-1602 induces, in a GPR3-independent manner, in Hep55B cells with elevated intracellular calcium. |
別名 | O1602, O 1602 |
分子量 | 258.36 |
分子式 | C17H22O2 |
CAS No. | 317321-41-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25.84 mg/mL (100 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
O-1602 317321-41-8 GPCR/G Protein Membrane transporter/Ion channel Metabolism Cannabinoid Receptor Calcium Channel O1602 O 1602 Inhibitor inhibitor inhibit